Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Détails
ID Serval
serval:BIB_DEFCAE3B18AD
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Périodique
Alzheimer's & dementia
Collaborateur⸱rice⸱s
“Hippocampus Study Group”, Hippocampus Study Group
Contributeur⸱rice⸱s
Godefroy O., Deramond H., Etcharry Bouyx F., Pasco Papon A., Dartigues J.F., Allard M., Rouaud O., Ricolfi F., Moreaud O., Krainik A., Pasquier F., Bombois S., Delmaire C., Couratier P., Maubon A., Vighetto A., Croisile B., Louis-Tisserand G., Ceccaldi M., Girard N., Michel B., Peretti M.P., Touchon J., Bonafe A., Benetos A., Barroche G., Bracard S., Vercelletto M., Calvier Auffray E., Robert P., Chanalet S., Dubois B., Dormont D., Lehericy S., Hugon J., Pancrazi M.P., Reizine D., Gil R., Vandermarcq P., Novella J.L., Pierot L., Belliard S., Carsin M., Martinaud O., Gerardin E., Laurent B., Barral F.G., Sellal F., Ousset P.J., Puel M., Ait Ameur A., Dumas H., Mondon K., Cottier J.P.
ISSN
1552-5279 (Electronic)
ISSN-L
1552-5260
Statut éditorial
Publié
Date de publication
09/2015
Peer-reviewed
Oui
Volume
11
Numéro
9
Pages
1041-1049
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD).
A double-blind, randomized, placebo-controlled parallel group design using donepezil (10 mg/day) in subjects with suspected prodromal AD. Subjects underwent two brain magnetic resonance imaging scans (baseline and final visit). The primary efficacy outcome was the annualized percentage change (APC) of total hippocampal volume (left + right) measured by an automated segmentation method.
Two-hundred and sixteen only subjects were randomized across 28 French expert clinical sites. In the per protocol population (placebo = 92 and donepezil = 82), the donepezil group exhibited a significant reduced rate of hippocampal atrophy (APC = -1.89%) compared with the placebo group (APC = -3.47%), P < .001. There was no significant difference in neuropsychological performance between treatment groups.
A 45% reduction of rate of hippocampal atrophy was observed in prodromal AD following 1 year of treatment with donepezil compared with placebo.
A double-blind, randomized, placebo-controlled parallel group design using donepezil (10 mg/day) in subjects with suspected prodromal AD. Subjects underwent two brain magnetic resonance imaging scans (baseline and final visit). The primary efficacy outcome was the annualized percentage change (APC) of total hippocampal volume (left + right) measured by an automated segmentation method.
Two-hundred and sixteen only subjects were randomized across 28 French expert clinical sites. In the per protocol population (placebo = 92 and donepezil = 82), the donepezil group exhibited a significant reduced rate of hippocampal atrophy (APC = -1.89%) compared with the placebo group (APC = -3.47%), P < .001. There was no significant difference in neuropsychological performance between treatment groups.
A 45% reduction of rate of hippocampal atrophy was observed in prodromal AD following 1 year of treatment with donepezil compared with placebo.
Mots-clé
Aged, Alzheimer Disease/drug therapy, Alzheimer Disease/pathology, Atrophy/drug therapy, Disease Progression, Donepezil, Double-Blind Method, Female, France, Hippocampus/drug effects, Hippocampus/pathology, Humans, Indans/adverse effects, Indans/therapeutic use, Magnetic Resonance Imaging, Male, Neuroprotective Agents/adverse effects, Neuroprotective Agents/therapeutic use, Organ Size, Piperidines/adverse effects, Piperidines/therapeutic use, Prodromal Symptoms, Treatment Outcome, Alzheimer's disease, Amnestic MCI, Biomarker, Hippocampus, MRI, Mild cognitive impairment, Prodromal Alzheimer's disease, Randomized controlled trial, Rate of atrophy, Therapy, Volumetric imaging, Whole brain analysis
Pubmed
Web of science
Création de la notice
23/08/2024 8:55
Dernière modification de la notice
11/09/2024 7:36
Données d'usage
